News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
For media inquiries, contact us at firstname.lastname@example.org
September 06, 2023COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
August 16, 2023COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
August 03, 2023COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
July 25, 2023First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
July 17, 2023COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
July 13, 2023Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin
July 06, 2023American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies
July 05, 2023COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
June 01, 2023Celebrating Pride 2023
To celebrate Pride, some members of our team tell us about LGBTQ+ people who inspire them.